The PACIFIC study: a phase 1b/2a study to investigate the safety, tolerability, pharmacology, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies [abstract 758] - Orevillo, C; Bialek, S; Dlugos, D; French, J; Kaye, R (2023)
, Dublin, Ireland. Accessed January 10, 2025 at: